4//SEC Filing
Vaishnaw Akshay 4
Accession 0001735276-23-000045
CIK 0001178670other
Filed
Apr 27, 8:00 PM ET
Accepted
Apr 28, 5:54 PM ET
Size
15.2 KB
Accession
0001735276-23-000045
Insider Transaction Report
Form 4
Vaishnaw Akshay
SVP, Clinical Research
Transactions
- Award
Common Stock
2023-04-26+5,312→ 20,282 total - Sale
Common Stock
2023-04-27$193.18/sh−197$38,056→ 20,085 total - Sale
Common Stock
2023-04-27$193.93/sh−910$176,476→ 19,175 total - Sale
Common Stock
2023-04-27$194.94/sh−1,013$197,474→ 18,162 total - Sale
Common Stock
2023-04-27$195.65/sh−104$20,348→ 18,058 total - Sale
Common Stock
2023-04-27$197.08/sh−168$33,109→ 17,890 total
Holdings
- 515(indirect: by Managed Account)
Common Stock
Footnotes (7)
- [F1]On February 23, 2022, the reporting person was granted performance-based stock units (PSUs) in connection with the issuer 2021 year-end compensation review. The PSUs vest in separate installments based on the achievement of three specified performance measures as determined by the People, Culture and Compensation Committee of the issuer Board of Directors. The shares reported were issued to the reporting person upon vesting of one-third of the PSUs based on achievement of a corresponding performance measure relating to the issuer public reporting of human proof-of-concept of an investigational therapeutic directed to an extrahepatic target (central nervous system, or CNS).
- [F2]Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of restricted stock units reported in this form.
- [F3]The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $ 192.47 to $193.47. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
- [F4]The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $ 193.48 to $194.48. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
- [F5]The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $ 194.49 to $195.49. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
- [F6]The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $ 195.50 to $196.09. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
- [F7]Reflects shares of ALNY common stock acquired by the reporting person under the issuer 401(k) plan as a result of the issuer 401(k) matching contribution program.
Documents
Issuer
ALNYLAM PHARMACEUTICALS, INC.
CIK 0001178670
Entity typeother
Related Parties
1- filerCIK 0001458494
Filing Metadata
- Form type
- 4
- Filed
- Apr 27, 8:00 PM ET
- Accepted
- Apr 28, 5:54 PM ET
- Size
- 15.2 KB